Prostate Cancer Risk Articles & Analysis: Older
8 articles found
Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's ...
By reducing the risk of a missed diagnosis, and giving us new insights into the development of the disease, AI could make a real difference for men facing a diagnosis of prostate ...
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. ...
Although the magnitude of the decline and recovery in health care visits vary by prostate cancer risk category, low-risk prostate cancer seems to have had the steepest drop.3 One study, performed in Massachusetts, reported the number of men tested for PSA per month fell 50%, with the biggest ...
It is a medication used to treat prostate cancer. It is used in combination with corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). ...
The Yukon chapter of Ride For Dad says a new blood test developed by an Alberta-based company could save the lives of men at risk of prostate cancer. (iStock/Getty Images) A bio-technology company based in Alberta is testing a new process that could result in fewer Yukon men travelling out of territory for prostate ...
Abstract Purpose: SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with traditional risk factors to individualize risk prediction for clinically significant prostate cancer. ...
Abstract Background: Prostate cancer (PCa) diagnosis is challenging because efforts for effective, timely treatment of men with significant cancer typically result in over-diagnosis and repeat biopsies. ...